Inverness Medical to acquire Binax

14 February 2005

US firm Inverness Medical Innovations, a manufacturer and marketer of consumer and professional diagnostic products and developer of advanced medical devices, has signed a definitive agreement to acquire Binax, a privately-held company located in Portland, Maine. Binax is a leading developer, manufacturer and distributor of rapid diagnostic products for infectious disease testing, primarily related to the respiratory system. Binax is a profitable company with sales in 2004 of approximately $20.0 million, noted Inverness.

Under the terms of the deal, Inverness will acquire all of the stock of Binax in exchange for 1,433,333 shares and an additional consideration of $8.6 million in cash at the closing of the acquisition. The accord also provides for a further consideration to the Binax shareholders of up to $11.0 million in cash, contingent upon the firm meeting certain new product development performance objectives over five years.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight